

LASA SUPERGENERICS LIMITED

CORPORATE OFFICE: B/207, City Point, Near Kohinoor Hotel, J B Nagar (Chakala) Metro Station, Andheri (E), Mumbai – 400059, Maharashtra, India. Tel: 022-4970 1092, Email: mail@lasalabs.com, Website: www.lasalabs.com

Ref. No.: LASA/SE/19-20/21 Monday August 12, 2019

То,	То,
Corporate Services Department	Corporate Services Department
BSE Limited	National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers,	"Exchange Plaza", Plot No. C/1,
Dalal Street,	G Block Bandra-Kurla Complex,
Mumbai – 400 001.	Bandra (E), Mumbai – 400 051.
BSE CODE –540702	NSE CODE: LASA

Dear Sir/Madam,

Sub. : Outcome of Board Meeting held today i.e. 12 August, 2019

Pursuant to Regulation 29 and Regulation 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we write to inform you that at the meeting held today at the Corporate Office of the Company which was commenced at 11.00 a.m. and concluded at 4.00 p.m. for the following Purpose:

- 1. Considered, approved and took on record the Unaudited Financial Results along with Limited Review Report for the quarter ended June 30, 2019.
- 2. Approved withdrawal of proposed rights issue subject to statutory approvals (if any) since the market price of the shares has fallen it is practically not possible for the company to come up with the issue.

A copy of the statement of Unaudited Financial Results along with Limited Review Report submitted by the Statutory Auditors of the Company is attached herewith.

The above information is also available on the company's website at <u>www.lasalabs.com</u> and on the website of the stock Exchange at <u>www.bseindia.com</u> and <u>www.nseindia.com</u>.

Please take the same for your information and for your records.

Yours Sincerely, For LASA SUPERGENERICS LIMITED

NIDHI KULSHRESTHA COMPANY SECRETARY AND COMPLIANCE OFFICER

CIN:L24233MH2016PLC274202

FACTORY & REGD. OFFICE: Plot No. C-105, MIDC, Mahad, Dist. Raigad, Maharashtra, India. Tel: +91-2145-232101/ 232202



LASA SUPERGENERICS LIMITED

Corporate Office : B/207, "CITI POINT", Near Kohinoor Hotel, J.B. Nagar, Andheri (E), Mumbai -59 Tel : +91 22 4970 1092 • Email : info@lasalabs.com • Website : www.lasalabs.com

Statement of Unaudited Financial Results for the Quarter ended 30th June, 2019

				(Rs. In Lakhs)
	Quarter ended			Year ended
Particulars	30.06.2019 (Unaudited)	31.03.2019 (Audited)	30.06.2018 (Unaudited)	31.03.2019 (Audited)
1. INCOME				
a. Revenue from Operations	3,898.40	4,202.38	3,292.06	16,957.30
b. Other Income	9.17	35.75	3.92	47.45
Total Income	3,907.57	4,238.13	3,295.98	17,004.75
2. Expenses				
a. Cost of Materials consumed	2,308.50	2,288.79	1,701.13	8,380.65
b. Cost of Traded Goods	49.41	884.07	599.79	4,240.38
c. Change in Inventories of Finished Goods, Work-in-Progress and Stock in trade	299.88	(183.74)	(184.29)	173.62
d. Employee benefits expenses	299.63	321.65	268.21	1,173.51
e. Finance costs	214.02	167.94	262.99	837.88
f. Depreciation & amortizations expenses	426.23	478.43	480.13	1,930.85
g. Other Expenses	437.84	584.05	385.65	1,878.14
Total Expenses (a to g)	4,035.51	4,541.20	3,513.61	18,615.03
Exceptional Items	1	2	-	
3. Profit / (Loss) before tax (1-2)	(127.94)	(303.07)	(217.63)	(1,610.28)
4. Tax expense	((,		
Current Tax				
Deferred Tax	(20.32)	(113.34)	79.97	(468.17)
Short / Excess income tax provision for earlier years	100	(9.74)		60.95
5. Net Profit / (Loss) after tax (3-4)	(107.62)	(179.99)	(297.60)	(1,203.06)
6. Other Comprehensive Income	(
Items that will not be reclassified Into Profit or Loss		(0.87)		(1.25)
- Remeasurement of Defined Benefit Plans (Net of tax)		(0.01)		(1.23)
7. Total Comprehensive Income for the year (after tax) (5+6)	(107.62)	(180.86)	(297.60)	(1,204.31)
8. Paid-up Equity Share Capital (Face Value of Re. 10 /- each)	2,286.44	2286.44	2,286.44	2,286.44
9. Other Equity excluding Revaluation reserve as per Balance Sheet	-		1	8,243.34
10. Earnings per Equity Share (of Rs. 10/- each) (a) Basic (b) Diluted	(0.47) (0.47)	(0.79) (0.79)		

Notes :

1) The Above Financial Results were reviewed by the audit committee of the board on 12th August, 2019 and approved by the Board of Directors of the company at their meeting held on same date. The Statutory auditors have expressed on unmodified opinion. The review report has been filed with stock exchange and is available on the company's website. The Financial results have been prepared in accoradance with Ind AS notified under the Companies (Accounting Standards) Rule, 2015.

2) Finance cost for the quarter ended 30th June, 2019 includes, Rs.48.85 Lacs on account of IND As effect given in respect of interest free unsecured loan received from the promoters of the company. As a result, Finance cost / loss for the quater is higher to that extent. Where as, Finance cost and loss for the quater ended 30th June, 2018 and year ended 31st March, 2019 was lower by Rs.6.34 Lacs and Rs.42.40 Lacs., respectively

3) Finance cost is net off Rs.8.79 Lakhs being profit on account of foreign exchange fluctuations and Rs.116.51 Lakhs being loss on account of foreign exchange fluctuations during the quarter ended 30th June, 2019 and 30 th June, 2018., respectively

4) The figures of the quarter ended 31st March, 2019 are the balancing figures between audited figures in respect of the full financial year and published year to date figures up to the third quarter of relevant financial year. Also the figures up to the end of third quarter were only reviewed and not subject to audit.

5) Effective April 1, 2018, the Company has adopted Indian Accounting Standard 115 - 'Revenue from Contract with Customers' with modified retrospective approach. Adoption of this standard did not have any material impact on the financial results of the Company.

6) The Company has single business segment i.e. Active Pharmaceutical Ingredients (API), therefore, in the context of Ind As 108, disclosure of segment information is not applicable.

7) Figures of previous period have been re-grouped / reclassified wherever necessary, to confirm to this period's classification.

By order of the Board of Directors For Lasa Supergenerics Limited Omkar Herlekar Chairman & Managing Director (DIN No. 01587154)

CIN: L24233MH2016PLC274202

Place : Mumbai

Date : 12th August, 2019

ire Rinwadi Dist - Raigad - 402309 Tel • 02145-232101 232202

V. K. Thanawala B.COM., F.C.A



LIMITED REVIEW REPORT

To, THE BOARD OF DIRECTORS LASA SUPERGENRICS LIMITED

- 1. We have reviewed the accompanying Statement of Unaudited Financial Results of Lasa Supergenrics Limited ("the Company") for the quarter ended June 30, 2019 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The figures up to the quarter ended were only reviewed and not subjected to audit. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
- 2. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the applicable Indian Accounting Standards (Ind AS) as prescribed under section 133 of Companies Act, 2013 read with rules issued there under and other recognised accounting practices and principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation And Disclosure Requirements) Regulation, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

MUMBAI M.No. 15632 Firm Reg. No.

110948W

For Thanawala & Company Chartered Accountants Firm Registration No.: 110948



Place: Mumbai, Date: 12th August, 2019

UDIN-19015632AAAACA3144